Management of Acute Kidney Injury (AKI)

Initial Assessment and Immediate Actions

The American Gastroenterological Association recommends diagnosing AKI using established criteria: increase in serum creatinine by ≥0.3 mg/dL within 48 hours or ≥50% from baseline, or urine output <0.5 mL/kg/h for >6 hours 1, 3
The American College of Clinical Pharmacy suggests reviewing and discontinuing all potentially nephrotoxic medications including NSAIDs, certain antibiotics, and contrast agents 1, 2
Hold diuretics, ACE inhibitors, ARBs, and vasodilators unless clinically contraindicated, as recommended by the European Association for the Study of the Liver 4, 5
Perform a rigorous search for infection, as suggested by the American Gastroenterological Association 1

For hypovolemic patients with cirrhosis and AKI, the European Association for the Study of the Liver recommends albumin 1 g/kg/day (maximum 100 g) for two consecutive days 1, 6
Monitor fluid balance with strict input/output measurements, as recommended by the American College of Clinical Pharmacy 2

For patients with cirrhosis and AKI, follow the International Club of Ascites (ICA) algorithm, which recommends removing risk factors, expanding plasma volume if hypovolemic, and administering albumin 1 g/kg for 2 days 4, 6
If no response after 48 hours and HRS criteria are met, initiate vasoconstrictors (terlipressin) with albumin, as suggested by the European Association for the Study of the Liver 6

Monitor serum electrolytes, BUN, creatinine frequently (every 4-6 hours initially), as recommended by the American College of Clinical Pharmacy 2
Check urine analysis for hematuria, proteinuria, or abnormal sediment to exclude structural renal diseases, as suggested by the American College of Clinical Pharmacy 2
Consider urinary biomarkers (NGAL) to distinguish between acute tubular necrosis and hepatorenal syndrome in cirrhotic patients, as recommended by the European Association for the Study of the Liver 6, 5

Delaying treatment of underlying causes, especially infections, as warned by the American Gastroenterological Association 1, 2
Continuing nephrotoxic medications during AKI recovery, as cautioned by the American College of Clinical Pharmacy 2
Neglecting to adjust medication dosages as kidney function changes, as advised by the American College of Clinical Pharmacy 2
Using the "triple whammy" combination of NSAIDs, diuretics, and ACE inhibitors/ARBs, as warned by the American College of Clinical Pharmacy 2

Consider RRT for severe oliguria unresponsive to fluid resuscitation, severe metabolic derangements, uremic symptoms, or fluid overload, as recommended by the American College of Clinical Pharmacy 2
In cirrhotic patients with HRS-AKI unresponsive to medical therapy, early consideration of RRT may be necessary, as suggested by the European Association for the Study of the Liver 6